Tag: delpacibart etedesiran
-
Novartis’ Del-desiran Fails Phase 3, Deepening a Week of Pipeline Setbacks
Novartis’ del-desiran missed the primary endpoint in the Phase 3 HARBOR trial for DM1, raising questions about the $12 billion Avidity acquisition and the clinical translation of its AOC platform.
-
How Toxic RNA Drives DM1—and Why Del-desiran Was Designed to Silence It
DM1 is driven by toxic CUG-repeat DMPK RNA that sequesters MBNL proteins and disrupts alternative splicing. This explainer examines how del-desiran was designed to correct that mechanism—and why molecular improvement did not translate into a positive Phase 3 primary endpoint.